A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-30

Study Completion Date

2028-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors

NCT03762447

Solid Tumors

COMPLETED PHASE1

Study of INCA 0186 in Subjects With Advanced Solid Tumors

NCT04989387

Advanced Solid Tumors Squamous Cell Carcinoma of the Head and Neck (SCCHN) Gastrointestinal (GI) Malignancies

TERMINATED PHASE1

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

NCT02712905

Solid Tumors and Hematologic Malignancy

TERMINATED PHASE1/PHASE2

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

NCT03522142

Advanced Solid Tumors

TERMINATED PHASE1

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

NCT02697591

Advanced Malignancies Metastatic Cancer

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumors Advanced Solid Tumors Metastatic Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1a: Dose Escalation monotherapy

INCB177054 at the protocol-defined dose strength based on cohort assignment.

Group Type EXPERIMENTAL

INCB177054

Intervention Type DRUG

INCB177054 will be administered at protocol defined dose.

Part 1b: Pharmacodynamic cohort

INCB177054 at the protocol-defined dose strength based on cohort assignment.

Group Type EXPERIMENTAL

INCB177054

Intervention Type DRUG

INCB177054 will be administered at protocol defined dose.

Part 1c: Dose Expansion monotherapy

INCB177054 at the protocol-defined dose strength based on cohort assignment.

Group Type EXPERIMENTAL

INCB177054

Intervention Type DRUG

INCB177054 will be administered at protocol defined dose.

Part 2a: Dose Escalation combination

INCB177054 in combination with retifanlimab at the protocol-defined dose strength based on cohort assignment.

Group Type EXPERIMENTAL

INCB177054

Intervention Type DRUG

INCB177054 will be administered at protocol defined dose.

Retifanlimab

Intervention Type DRUG

Retifanlimab will be administered at protocol defined dose.

Part 2b: Dose Expansion combination

INCB177054 in combination with retifanlimab at the protocol-defined dose strength based on cohort assignment.

Group Type EXPERIMENTAL

INCB177054

Intervention Type DRUG

INCB177054 will be administered at protocol defined dose.

Retifanlimab

Intervention Type DRUG

Retifanlimab will be administered at protocol defined dose.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

INCB177054

INCB177054 will be administered at protocol defined dose.

Intervention Type DRUG

Retifanlimab

Retifanlimab will be administered at protocol defined dose.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Anticipated life expectancy greater than 12 weeks.
* ECOG performance status score of 0 or 1.
* Measurable disease per RECIST v1.1 on CT or MRI.
* Part 1a and 2a (dose escalation) and Part 1c (dose expansion): participants who have a confirmed tissue diagnosis of a solid malignant tumor that is progressing and not amenable to curative surgery or other curative treatment modalities.

* Part 1a (monotherapy): Participants must have had disease progression on/after prior treatment and have been considered for all standard available therapies (have disease progression on all available standard treatment options or are intolerant or ineligible to them or has refused available options approved in the region).
* Part 2a (combination): participants with advanced malignant tumors for whom immunotherapy is an appropriate treatment option.
* Part 1b incurable locally recurrent or metastatic HNSCC:

* Tissue diagnosis of HNSCC.
* Locally recurrent disease must not be amenable to therapy (surgery and/or radiation therapy with or without chemotherapy) with curative intent. Participants who refuse curative salvage surgery for locally recurrent disease are ineligible.
* Eligible primary tumor locations include oral cavity, oropharynx, hypopharynx, or larynx. Primary tumors of the nasopharynx, sinonasal cavity, or salivary gland are excluded.
* Part 2b combination dose-expansion cohorts in locally advanced or metastatic SCAC (Group 1), metastatic PD-L1-positive (TPS ≥ 50%) NSCLC (Group 2), or locally recurrent or metastatic PD-L1-positive (CPS ≥ 1%) HNSCC (Group 3) (Primary tumors of the nasopharynx, sinonasal cavity, or salivary gland are excluded).
* Availability of a baseline archival tumor specimen or willingness to undergo a pretreatment biopsy to obtain.
* If HIV-positive, CD4+ count must be greater than or equal to 350 cells/μL, must have undetectable viral load per standard of care assay, and receiving antiretroviral therapy not containing a moderate or potent CYP3A4/CYP3A5 inhibitor or inducer for at least 4 weeks prior to study enrollment, and have not had any HIV-related opportunistic infection for at least 4 weeks prior to study enrollment.
* Willingness to avoid pregnancy or fathering children.

Exclusion Criteria

* Known additional invasive malignancy within 1 year of the first dose of study drug.
* Known active CNS metastases and/or carcinomatous meningitis and/or leptomeningeal disease, or evidence of progression of previously treated CNS metastases.
* Prior treatment with a DGK inhibitor.
* Receipt of anticancer medications, investigational drugs, or other interventional clinical studies within 5 half-lives or 28 days before the first administration of study drug.
* History of organ transplant, including allogeneic stem cell transplantation.
* Radiation therapy administered within 28 days of the start of treatment.
* Any residual toxic effects ≥ Grade 2 from prior therapy or surgery.
* Any immune-related toxicity during prior immune therapy for which permanent discontinuation or prolonged immunosuppression was recommended to manage.
* Laboratory values specified at screening.
* Significant concurrent, uncontrolled medical conditions, including but not limited to hepatic, gastrointestinal conditions, pulmonary, cardiovascular, and active autoimmune disease.
* Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.
* Active HBV or HCV.
* Prohibited medication per protocol.
* Hypersensitivity to any component of study treatment or formulation components.
* Women who are pregnant or breastfeeding.
* Has received a live vaccine within 28 days of the planned start of study treatment.
* Any condition that would interfere with participation.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No